-
Crestor Label Changes from March 2005 Not Posted on FDA MedWatch Site Until May 2005
Crestor Package Insert Label Changes Include Rhabdomyolysis Risk In March 2005 the FDA and AstraZeneca reached agreement about making certain changes to the package insert label for the pharmaceutical company’s cholesterol-lowering drug Crestor (rosuvastatin). …
-
Sudden Cardiac Death Caused by Some Commonly Prescribed Drugs
Increased Risk of Sudden Death Linked to Use of Some Widely Used Medications A study which analyzed 775 cases of sudden cardiac deaths in the Netherlands has found some commonly prescribed drugs may interfere…
-
Medicare to Aid FDA by Creation of Drug-safey Database
Serious Side Effects and Other Safety Issues Would be Discovered Sooner In an effort to reduce delay in the issuance of FDA safety recalls of drugs, Medicare wants to create a massive electronic database…
-
Recalled Drug Bextra Might Return to U.S. Market
FDA Had Pfizer Pull Bextra Because of Serious Skin Reaction Side Effects Pfizer Inc. wants its arthritis drug Bextra returned to the U.S. market and plans to discuss with the FDA how it might…
-
Baycol Cases Settled to Date: 2,995 Claims Paid Total of $1.133 Billion
About 6,000 Baycol Lawsuits Remain In U.S.; Bayer Says Only 50 of Those Cases to be Settled At Bayer AG’s annual general meeting in late April 2005, the company said that as of April…
-
New “Drug Watch” Web Page for Drug-safety Information
Emerging Drug-safety Issues Will be Posted on New FDA Site Late last week the FDA announced guidelines for its proposed "Drug Watch" web site, which would be aimed at letting patients know about emerging…
